A large study found that Vegovi, a weight-loss and blood sugar control drug, reduced cardiovascular risk by 20%. The study was published in the journal NEJM.
More than 17.5 thousand people from 41 countries participated in the study financed by the manufacturer. All were over 45 years old and had a body mass index of 27 or higher, which is considered overweight or obese. They were followed for an average of three years. Patients were taking medications to treat cardiovascular disease. Half of them also received weekly injections of Vegovi or a placebo, a medicine without the active ingredient.
The study found that 6.5% of people taking Vegovi experienced heart attack, stroke, or death from causes related to heart disease. The proportion of such patients in the placebo group was 8%; This means Vegovi is associated with a 20% reduction in cardiovascular risk.
Those taking Vegovi lost about 9% of their body weight, while the placebo group lost less than 1%. Reduced inflammation, lowered cholesterol, blood sugar and blood pressure; all of which may help reduce cardiovascular risk.
It remains unclear whether the results are a side effect of the weight loss or directly related to the drug. Vegovi also has serious side effects that limit its use: About 17% of patients discontinued the study due to nausea, vomiting, diarrhea and other gastrointestinal problems.
Previous scientists to create A way to detect stomach cancer at an early stage with 90% accuracy.